Startups
Established in 1958 and headquartered in Jinan, China, Qilu Pharmaceuticals is a large and comprehensive pharmaceutical company specializing in R&D, manufacture, sales and international trade of both APIs and drug products.
Overview
Location
China, Shandong, Jinan City
Employees
10001+
Founded date
1958
Mentions in press and media 15
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 9, 2026 | Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 | CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive prof... |
| Jun 1, 2026 | Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting | HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today ... |
| Sep 17, 2025 | Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) | EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) a... |
| Jul 28, 2025 | Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)' | CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® bi... |
| Dec 26, 2024 | Haikou delivers mix of tradition and cutting-edge industry | BEIJING, Dec. 26, 2024 /PRNewswire/ -- A news report from China Daily: For all tourists to Haikou, capital of South China's Hainan province, Qilou Old Street is a must-go spot. With hundreds of old buildings dating back to 1840s, the street... |
| Jun 7, 2024 | Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024 | JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened from May 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studie... |
| Mar 15, 2024 | Qilu Pharmaceutical Showcases QL1706 Clinical Trial Outcomes in Oral Presentation at ESGO 2024 | JINAN, China, March 15, 2024 /PRNewswire/ -- On 8 March local time, during the 25th European Society of Gynecological Oncology (ESGO) Conference (ESGO 2024) in Spain, Qilu Pharmaceutical unveiled the Phase II clinical trial results for ipar... |
| Sep 26, 2022 | CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy | HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-sh... |
| Sep 5, 2022 | CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop "off-the-shelf" CAR-iMAC cell therapy | HANGZHOU, China, Sept. 5, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprieta... |
Show more
Reviews 0
FAQ about Qilu Pharmaceutical
When was Qilu Pharmaceutical founded?
Qilu Pharmaceutical was founded in 1958.
What has the press written about Qilu Pharmaceutical?
Parsers VC has collected 15 articles mentioning Qilu Pharmaceutical, among them “Insilico Medicine Releases Positive Profit Alert for the First Half of 2026” (Jul 9, 2026) and “Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Pati...” (Jun 1, 2026).
Is Qilu Pharmaceutical still active?
Yes, Qilu Pharmaceutical is active; its latest activity on Parsers VC dates from Jul 24, 2026.